Iron oxide nanoparticles aggravate hepatic steatosis and liver injury in nonalcoholic fatty liver disease through BMP-SMAD-mediated hepatic iron overload

References

• Ahmed, U., P. S. Latham, and P. S. Oates. 2012. “Interactions between Hepatic Iron and Lipid Metabolism with Possible Relevance to Steatohepatitis.” World Journal of Gastroenterology 18 (34): 4651–4658. doi:10.3748/wjg.v18.i34.4651.
   PubMed Web of Science ®Google Scholar
• Angulo, P. 2002. “Nonalcoholic Fatty Liver Disease.” New England Journal of Medicine 346 (16): 1221–1231. doi:10.1056/NEJMra011775.
   PubMed Web of Science ®Google Scholar
• Bashir, M. R., L. Bhatti, D. Marin, and R. C. Nelson. 2015. “Emerging Applications for Ferumoxytol as a Contrast Agent in Mri.” Journal of Magnetic Resonance Imaging 41 (4): 884–898. doi:10.1002/jmri.24691.
   PubMed Web of Science ®Google Scholar
• Britton, Laurence, Kim Bridle, Janske Reiling, Nishreen Santrampurwala, Leesa Wockner, Helena Ching, Katherine Stuart, et al. 2018. “Hepatic Iron Concentration Correlates with Insulin Sensitivity in Nonalcoholic Fatty Liver Disease.” Hepatology Communications 2 (6): 644–653. doi:10.1002/hep4.1190.
   PubMed Web of Science ®Google Scholar
• Britton, L. J., V. N. Subramaniam, and D. H. Crawford. 2016. “Iron and Non-Alcoholic Fatty Liver Disease.” World Journal of Gastroenterology 22 (36): 8112–8122. doi:10.3748/wjg.v22.i36.8112.
   PubMed Web of Science ®Google Scholar
• Buzzetti, Elena, Salvatore Petta, Roberta Manuguerra, Tu Vinh Luong, Daniela Cabibi, Elena Corradini, Antonio Craxì, et al. 2019. “Evaluating the Association of Serum Ferritin and Hepatic Iron with Disease Severity in Non-Alcoholic Fatty Liver Disease.” Liver International 39 (7): 1325–1334. doi:10.1111/liv.14096.
   PubMed Web of Science ®Google Scholar
• Chalasani, Naga, Zobair Younossi, Joel E. Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A. Harrison, et al. 2018. “The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases.” Hepatology 67 (1): 328–357. doi:10.1002/hep.29367.
   PubMed Web of Science ®Google Scholar
• Chen, H. 2020. “Nutrient mtorc1 Signaling Contributes to Hepatic Lipid Metabolism in the Pathogenesis of Non-Alcoholic Fatty Liver Disease.” Liver Research 4 (1): 15–22. doi:10.1016/j.livres.2020.02.004.
   Google Scholar
• Chen, Hanqing, Feng Shen, Alex Sherban, Allison Nocon, Yu Li, Hua Wang, Ming-Jiang Xu, et al. 2018. “Dep Domain-Containing Mtor-Interacting Protein Suppresses Lipogenesis and Ameliorates Hepatic Steatosis and Acute-on-Chronic Liver Injury in Alcoholic Liver Disease.” Hepatology 68 (2): 496–514. doi:10.1002/hep.29849.
   PubMed Web of Science ®Google Scholar
• Chen, Hanqing, Bing Wang, Weiyue Feng, Wei Du, Hong Ouyang, Zhifang Chai, Xiaolin Bi, et al. 2015. “Oral Magnetite Nanoparticles Disturb the Development of drosophila melanogaster from Oogenesis to Adult Emergence.” Nanotoxicology 9 (3): 302–312. doi:10.3109/17435390.2014.929189.
   PubMed Web of Science ®Google Scholar
• Chen, Hanqing, Ruifang Zhao, Bing Wang, Chengxu Cai, Lingna Zheng, Hailong Wang, Meng Wang, et al. 2017. “The Effects of Orally Administered ag, TiO2 and SiO2 Nanoparticles on Gut Microbiota Composition and Colitis Induction in Mice.” NanoImpact 8: 80–88. doi:10.1016/j.impact.2017.07.005.
   Web of Science ®Google Scholar
• Cotter, T. G., and M. Rinella. 2020. “Nonalcoholic Fatty Liver Disease 2020: The State of the Disease.” Gastroenterology 158 (7): 1851–1864. doi:10.1053/j.gastro.2020.01.052.
   PubMed Web of Science ®Google Scholar
• Dadfar, Seyed Mohammadali, Karolin Roemhild, Natascha I. Drude, Saskia von Stillfried, Ruth Knüchel, Fabian Kiessling, Twan Lammers, et al. 2019. “Iron Oxide Nanoparticles: Diagnostic, Therapeutic and Theranostic Applications.” Advanced Drug Delivery Reviews 138: 302–325. doi:10.1016/j.addr.2019.01.005.
   PubMed Web of Science ®Google Scholar
• Das, S. K., J. DesAulniers, J. R. Dyck, Z. Kassiri, and G. Y. Oudit. 2016. “Resveratrol Mediates Therapeutic Hepatic Effects in Acquired and Genetic Murine Models of Iron-Overload.” Liver International 36 (2): 246–257. doi:10.1111/liv.12893.
   PubMed Web of Science ®Google Scholar
• Dukhinova, M. S., A. Y. Prilepskii, A. A. Shtil, and V. V. Vinogradov. 2019. “Metal Oxide Nanoparticles in Therapeutic Regulation of Macrophage Functions.” Nanomaterials 9 (11): 1631. doi:10.3390/nano9111631.
   Web of Science ®Google Scholar
• Eder, Sebastian K., Alexandra Feldman, Georg Strebinger, Jana Kemnitz, Stephan Zandanell, David Niederseer, Michael Strasser, et al. 2020. “Mesenchymal Iron Deposition is Associated with Adverse Long-Term Outcome in Non-Alcoholic Fatty Liver Disease.” Liver International 40 (8): 1872–1882. doi:10.1111/liv.14503.
   PubMed Web of Science ®Google Scholar
• Handa, Priya, Bryan D. Maliken, James E. Nelson, Kelly A. Hennessey, L. Akhila Vemulakonda, Vicki Morgan-Stevenson, Barjinder K. Dhillon, et al. 2017. “Differences in Hepatic Expression of Iron, Inflammation and Stress-Related Genes in Patients with Nonalcoholic Steatohepatitis.” Annals of Hepatology 16 (1): 77–85. doi:10.5604/16652681.1226818.
   PubMed Web of Science ®Google Scholar
• Handa, Priya, Vicki Morgan-Stevenson, Bryan D. Maliken, James E. Nelson, Shenna Washington, Mark Westerman, Matthew M. Yeh, et al. 2016. “Iron Overload Results in Hepatic Oxidative Stress, Immune Cell Activation, and Hepatocellular Ballooning Injury, Leading to Nonalcoholic Steatohepatitis in Genetically Obese Mice.” American Journal of Physiology-Gastrointestinal and Liver Physiology 310 (2): G117–G127. doi:10.1152/ajpgi.00246.2015.
   PubMed Web of Science ®Google Scholar
• Hasebe, Takumu, Hiroki Tanaka, Koji Sawada, Shunsuke Nakajima, Takaaki Ohtake, Mikihiro Fujiya, Yutaka Kohgo, et al. 2017. “Bone Morphogenetic Protein-Binding Endothelial Regulator of Liver Sinusoidal Endothelial Cells Induces Iron Overload in a Fatty Liver Mouse Model.” Journal of Gastroenterology 52 (3): 341–351. doi:10.1007/s00535-016-1237-6.
   PubMed Web of Science ®Google Scholar
• Kim, Hye Young, Woo Young Kwon, Joon Beom Park, Mi Hwa Lee, Yoo Jin Oh, SungHwan Suh, Yang Hyun Baek, et al. 2020. “Hepatic stamp2 Mediates Recombinant fgf21-Induced Improvement of Hepatic Iron Overload in Nonalcoholic Fatty Liver Disease.” The FASEB Journal 34 (9): 12354–12366. doi:10.1096/fj.202000790R.
   PubMed Web of Science ®Google Scholar
• Lambert, J. E., M. A. Ramos-Roman, J. D. Browning, and E. J. Parks. 2014. “Increased de Novo Lipogenesis is a Distinct Characteristic of Individuals with Nonalcoholic Fatty Liver Disease.” Gastroenterology 146 (3): 726–735. doi:10.1053/j.gastro.2013.11.049.
   PubMed Web of Science ®Google Scholar
• Li, Min, Yuxiao Tang, Lusha Wu, Fengfeng Mo, Xin Wang, Hongxia Li, Ruirui Qi, et al. 2017. “The Hepatocyte-Specific hnf4α/Mir-122 Pathway Contributes to Iron Overload–Mediated Hepatic Inflammation.” Blood 130 (8): 1041–1051. doi:10.1182/blood-2016-12-755967.
   PubMed Web of Science ®Google Scholar
• Li, Xue, Bing Wang, Shuang Zhou, Wei Chen, Hanqing Chen, Shanshan Liang, Lingna Zheng, et al. 2020. “Surface Chemistry Governs the Sub-Organ Transfer, Clearance and Toxicity of Functional Gold Nanoparticles in the Liver and Kidney.” Journal of Nanobiotechnology 18 (1): 45. doi:10.1186/s12951-020-00599-1.
   PubMed Web of Science ®Google Scholar
• Liang, Huan, Hui Huang, Pei-zhu Tan, Ying Liu, Jun-hui Nie, Yi-tong Zhang, Kai-li Zhang, et al. 2017. “Effect of Iron on Cholesterol 7α-Hydroxylase Expression in Alcohol-Induced Hepatic Steatosis in Mice.” Journal of Lipid Research 58 (8): 1548–1560. doi:10.1194/jlr.M074534.
   PubMed Web of Science ®Google Scholar
• Lim, Pei Jin, Tiago L. Duarte, João Arezes, Daniel Garcia-Santos, Amel Hamdi, Sant-Rayn Pasricha, Andrew E. Armitage, et al. 2019. “Nrf2 Controls Iron Homeostasis in Haemochromatosis and Thalassaemia via bmp6 and Hepcidin.” Nature Metabolism 1 (5): 519–531. doi:10.1038/s42255-019-0063-6.
   PubMedGoogle Scholar
• Lu, S., R. G. Bennett, K. K. Kharbanda, and D. D. Harrison-Findik. 2016. “Lack of Hepcidin Expression Attenuates Steatosis and Causes Fibrosis in the Liver.” World Journal of Hepatology 8 (4): 211–225. doi:10.4254/wjh.v8.i4.211.
   PubMed Web of Science ®Google Scholar
• Ma, B., H. Sun, B. Zhu, S. Wang, L. Du, X. Wang, Qu, S. 2021. “Hepatic Steatosis is Associated with Elevated Serum Iron in Patients with Obesity and Improves after Laparoscopic Sleeve Gastrectomy.” Obesity Facts 14: 64–71.
   PubMed Web of Science ®Google Scholar
• MacParland, Sonya A., Kim M. Tsoi, Ben Ouyang, Xue-Zhong Ma, Justin Manuel, Ali Fawaz, Mario A. Ostrowski, et al. 2017. “Phenotype Determines Nanoparticle Uptake by Human Macrophages from Liver and Blood.” ACS Nano 11 (3): 2428–2443. doi:10.1021/acsnano.6b06245.
   PubMed Web of Science ®Google Scholar
• Maliken, B. D., J. E. Nelson, H. M. Klintworth, M. Beauchamp, M. M. Yeh, and K. V. Kowdley. 2013. “Hepatic Reticuloendothelial System Cell Iron Deposition is Associated with Increased Apoptosis in Nonalcoholic Fatty Liver Disease.” Hepatology 57 (5): 1806–1813. doi:10.1002/hep.26238.
   PubMed Web of Science ®Google Scholar
• Mehta, K. J., S. J. Farnaud, and P. A. Sharp. 2019. “Iron and Liver Fibrosis: Mechanistic and Clinical Aspects.” World Journal of Gastroenterology 25 (5): 521–538. doi:10.3748/wjg.v25.i5.521.
   PubMed Web of Science ®Google Scholar
• Mirea, Andreea-Manuela, Rinke Stienstra, Thirumala-Devi Kanneganti, Cees J. Tack, Triantafyllos Chavakis, Erik J. M. Toonen, Leo A. B. Joosten, et al. 2020. “Mice Deficient in the il-1beta Activation Genes prtn3, Elane, and casp1 Are Protected against the Development of Obesity-Induced Nafld.” Inflammation 43 (3): 1054–1064. doi:10.1007/s10753-020-01190-4.
   PubMed Web of Science ®Google Scholar
• Miyanishi, K., S. Tanaka, H. Sakamoto, and J. Kato. 2019. “The Role of Iron in Hepatic Inflammation and Hepatocellular Carcinoma.” Free Radical Biology and Medicine 133: 200–205. doi:10.1016/j.freeradbiomed.2018.07.006.
   PubMed Web of Science ®Google Scholar
• Nelson, J. E., H. Klintworth, and K. V. Kowdley. 2012. “Iron Metabolism in Nonalcoholic Fatty Liver Disease.” Current Gastroenterology Reports 14 (1): 8–16. doi:10.1007/s11894-011-0234-4.
   PubMedGoogle Scholar
• Poller, Wolfram C., Melanie Pieber, Philipp Boehm-Sturm, Evelyn Ramberger, Vasileios Karampelas, Konstantin Möller, Moritz Schleicher, et al. 2018. “Very Small Superparamagnetic Iron Oxide Nanoparticles: Long-Term Fate and Metabolic Processing in Atherosclerotic Mice.” Nanomedicine: Nanotechnology, Biology and Medicine 14 (8): 2575–2586. doi:10.1016/j.nano.2018.07.013.
   PubMed Web of Science ®Google Scholar
• Poon, Wilson, Yi-Nan Zhang, Ben Ouyang, Benjamin R. Kingston, Jamie L. Y. Wu, Stefan Wilhelm, Warren C. W. Chan, et al. 2019. “Elimination Pathways of Nanoparticles.” ACS Nano 13 (5): 5785–5798. doi:10.1021/acsnano.9b01383.
   PubMed Web of Science ®Google Scholar
• Provenzano, R., B. Schiller, M. Rao, D. Coyne, L. Brenner, and B. J. G. Pereira. 2009. “Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis Patients.” Clinical Journal of the American Society of Nephrology 4 (2): 386–393. doi:10.2215/CJN.02840608.
   PubMed Web of Science ®Google Scholar
• Ryan, John D., Andrew E. Armitage, Jeremy F. Cobbold, Rajarshi Banerjee, Oscar Borsani, Paola Dongiovanni, Stefan Neubauer, et al. 2018. “Hepatic Iron is the Major Determinant of Serum Ferritin in Nafld Patients.” Liver International 38 (1): 164–173. doi:10.1111/liv.13513.
   PubMed Web of Science ®Google Scholar
• Salimi, Marzieh, Saeed Sarkar, Samaneh Fathi, Alimohammad Alizadeh, Reza Saber, Fatemeh Moradi, Hamid Delavari, et al. 2018. “Biodistribution, Pharmacokinetics, and Toxicity of Dendrimer-Coated Iron Oxide Nanoparticles in Balb/c Mice.” International Journal of Nanomedicine 13: 1483–1493. doi:10.2147/IJN.S157293.
   PubMed Web of Science ®Google Scholar
• Schuster, S., D. Cabrera, M. Arrese, and A. E. Feldstein. 2018. “Triggering and Resolution of Inflammation in Nash.” Nature Reviews Gastroenterology & Hepatology 15 (6): 349–364. doi:10.1038/s41575-018-0009-6.
   PubMed Web of Science ®Google Scholar
• Shimano, H., and R. Sato. 2017. “Srebp-Regulated Lipid Metabolism: Convergent Physiology – Divergent Pathophysiology.” Nature Reviews Endocrinology 13 (12): 710–730. doi:10.1038/nrendo.2017.91.
   PubMed Web of Science ®Google Scholar
• Smits, Loek P., Bram F. Coolen, Maria D. Panno, Jurgen H. Runge, Wouter H. Nijhof, Joanne Verheij, Max Nieuwdorp, et al. 2016. “Noninvasive Differentiation between Hepatic Steatosis and Steatohepatitis with MR Imaging Enhanced with Uspios in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study.” Radiology 278 (3): 782–791. doi:10.1148/radiol.2015150952.
   PubMed Web of Science ®Google Scholar
• Tsoi, Kim M., Sonya A. MacParland, Xue-Zhong Ma, Vinzent N. Spetzler, Juan Echeverri, Ben Ouyang, Saleh M. Fadel, et al. 2016. “Mechanism of Hard-Nanomaterial Clearance by the Liver.” Nature Materials 15 (11): 1212–1221. doi:10.1038/nmat4718.
   PubMed Web of Science ®Google Scholar
• Wei, Y., M. Zhao, F. Yang, Y. Mao, H. Xie, and Q. Zhou. 2016. “Iron Overload by Superparamagnetic Iron Oxide Nanoparticles is a High Risk Factor in Cirrhosis by a Systems Toxicology Assessment.” Scientific Reports 6 (1): 29110. doi:10.1038/srep29110.
   PubMedGoogle Scholar
• Xiaoli, A. M., Z. Song, and F. Yang. 2019. “Lipogenic Srebp-1a/c Transcription Factors Activate Expression of the Iron Regulator Hepcidin, Revealing Cross-Talk between Lipid and Iron Metabolisms.” Journal of Biological Chemistry 294 (34): 12743–12753. doi:10.1074/jbc.RA119.009644.
   PubMed Web of Science ®Google Scholar
• Younossi, Zobair, Frank Tacke, Marco Arrese, Barjesh Chander Sharma, Ibrahim Mostafa, Elisabetta Bugianesi, Vincent Wai-Sun Wong, et al. 2019. “Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.” Hepatology 69 (6): 2672–2682. doi:10.1002/hep.30251.
   PubMed Web of Science ®Google Scholar
• Zhao, R., M. Zhu, S. Zhou, W. Feng, and H. Chen. 2020. “Rapamycin-Loaded Mpeg-Plga Nanoparticles Ameliorate Hepatic Steatosis and Liver Injury in Non-Alcoholic Fatty Liver Disease.” Frontiers in Chemistry 8: 407–407.
   PubMed Web of Science ®Google Scholar
• Zhou, Q., and Y. Wei. 2017. “For Better or Worse, Iron Overload by Superparamagnetic Iron Oxide Nanoparticles as a MRI Contrast Agent for Chronic Liver Diseases.” Chemical Research in Toxicology 30 (1): 73–80. doi:10.1021/acs.chemrestox.6b00298.
   PubMed Web of Science ®Google Scholar
• Zhou, Shuang, Xue Li, Meilin Zhu, Hongyang Yu, Runxuan Chu, Wei Chen, Bing Wang, et al. 2020. “Hepatic Impacts of Gold Nanoparticles with Different Surface Coatings as Revealed by Assessing the Hepatic Drug-Metabolizing Enzyme and Lipid Homeostasis in Mice.” NanoImpact 20: 100259. doi:10.1016/j.impact.2020.100259.
   Web of Science ®Google Scholar
• Zhou, Jianghua, Feng Zhou, Wenxin Wang, Xiao‐Jing Zhang, Yan‐Xiao Ji, Peng Zhang, Zhi‐Gang She, et al. 2020. “Epidemiological Features of Nafld from 1999 to 2018 in china.” Hepatology 71 (5): 1851–1864. doi:10.1002/hep.31150.
   PubMed Web of Science ®Google Scholar